Telix Pharmaceuticals Limited (ASX:TLX)
Australia flag Australia · Delayed Price · Currency is AUD
13.24
-0.16 (-1.16%)
Nov 17, 2026, 11:35 AM AEDT

Telix Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $24.17. The average 1-year stock price forecast is 82.62% higher than the current stock price, while the lowest is $18.80 (+42.05%) and the highest is $31.50 (+138.01%).

Price Target: $24.17 (+82.62%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$18.80$24.17$21.50$31.50
Change+42.05%+82.62%+62.45%+138.01%

Analyst Ratings

The average analyst rating for Telix Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy898866
Buy654445
Hold013121
Sell000000
Strong Sell000000
Total141515131212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$31.50
BuyMaintains$31.50+138.01%Nov 8, 2026
Jarden
Jarden
Buy
Maintains
$21.00
BuyMaintains$21.00+58.67%Nov 6, 2026
Citi
Citi
Buy
Maintains
$31.00
BuyMaintains$31.00+134.23%Nov 4, 2026
UBS
UBS
Buy
Maintains
$26.00
BuyMaintains$26.00+96.45%Nov 4, 2026
Unknown Analyst
Ord Minnett
No rating
Ord Minnett
Buy
Maintains
$22.00 → $18.80
BuyMaintains$22.00 → $18.80+42.05%Oct 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
939.09M
from 803.79M
Increased by 16.83%
Revenue Next Year
1.07B
from 939.09M
Increased by 13.81%
EPS This Year
0.05
from -0.02
EPS Next Year
-0.01
from 0.05
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Jan 1, 2024Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
5.52M108.81M332.98M516.55M803.79M939.09M
Revenue Growth
37.33%1,870.12%206.01%55.13%55.61%16.83%
Gross Profit
3.67M64.52M203.28M319.49M381.85M522.46M
Gross Margin
66.46%59.29%61.05%61.85%47.51%55.64%
Operating Income
-59.08M-50.37M34.98M55.88M19.29M37.57M
Net Income
-58.54M-70.74M4.21M33.69M-7.13M18.17M
EPS
-----0.020.05
Forward PE
--32.8387.27282.12188.75
Free Cash Flow
-----40.89M14.36M
No. Analysts
-----14
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High973.6M
Avg939.1M
Low923.8M

Revenue Growth

Revenue Growth202620272028
High
21.1%
Avg
16.8%
Low
14.9%

EPS Forecast

EPS202620272028
High0.14
Avg0.05
Low-0.03

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-